| DB ID | MyCo_3115 |
| Title | Diagnostic performance of 1,3-beta-D-glucan serum screening in patients receiving hematopoietic stem cell transplantation |
| Year | 2016 |
| PMID | 26992092 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Patients receiving hematopoietic stem cell transplantation |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The study protocol was approved by the local ethics committee, Medical University Graz, Austria (EC-number 23-343). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | This prospective single-center study was conducted at the Medical University Hospital of Graz, Austria, between September 2014 and August 2015. Adult patients (>18 years of age) who were admitted to the bone marrow transplantation unit or the hematology ward, and received HSCT or had a recent history of HSCT (i.e., receipt of HSCT within a year before admission) were identified. After informed consent was obtained, these patients were followed prospectively using clinical rounds, chart reviews, and surveys of electronic documents including microbiological test results. Twice weekly routine serum BDG screening was performed in all hematological malignancy patients who participated in this study until resolution of risk for developing IFI (e.g., recovery of neutropenia), dis- charge, or death. Serum samples that were obtained (i) between the beginning of myeloablative therapy up to 30 days after receipt of HSCT (defined as early phase), or (ii) >30 days but <1 year after allogeneic HSCT (defined as late phase) were included in this analysis. |
| Cohort No. | 45 |
| Age Group | None |
| P Value | p<0.001 |
| Sensitivity | 0.81 |
| Specificity | 0.98 |
| Positive Predictive Value | 0.65 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Patients with underlying hematological malignancies who are receiving allogeneic or autologous hematopoietic stem cell transplantation (HSCT) are considered a highly vulnerable group for invasive fungal infection (IFI) development (1–3). Therefore, early detection and treatment of IFIs are crucial to improve survival. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
